Neoadjuvant atezolizumab plus chemotherapy in resectable non-small cell lung cancer (NSCLC).

被引：37
|
作者：
Shu, Catherine A.
Grigg, Claud
Chiuzan, Codruta
Garofano, Robert F.
Patel, Vijeta
Hernandez, Susana
Negri, Tiffany
Sacher, Adrian G.
Smith-Marrone, Stephanie
Stoopler, Mark
Gainor, Justin F.
Awad, Mark M.
D'Ovidio, Frank
Sonett, Joshua R.
Bacchetta, Matthew
Saqi, Anjali
Rizvi, Naiyer A.
机构：
[1] Columbia Univ, Med Ctr, New York, NY USA
[2] Dana Farber Canc Inst, Boston, MA USA
[3] Massachusetts Gen Hosp, Boston, MA USA
[4] Massachusetts Gen Hosp, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.8532
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8532
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant atezolizumab plus chemotherapy in resectable non-small-cell lung cancer
    Rosell, Rafael
    Ito, Masaoki
    LANCET ONCOLOGY, 2020, 21 (06): : 736 - 738
  • [2] 3-year update of neoadjuvant atezolizumab plus chemotherapy in patients with resectable non-small cell lung cancer
    Henick, Brian S.
    Gainor, Justin F.
    Awad, Mark M.
    Chiuzan, Codruta
    Izard, Stephanie
    Georgis, Yohanna
    Koch, Peter D.
    Garofano, Robert F.
    Wong, Cheryl V.
    Saqi, Anjali
    Grindheim, Jessica M.
    Schulze, Katja
    Rizvi, Naiyer A.
    Izar, Benjamin
    Taylor, Alison M.
    Shu, Catherine A.
    CANCER RESEARCH, 2023, 83 (08)
  • [3] Neoadjuvant immunochemotherapy with pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
    Chen, Yulong
    Yan, Bo
    Zhang, Ran
    Zhao, Gang
    You, Jian
    HELIYON, 2023, 9 (09)
  • [4] Neoadjuvant chemotherapy for resectable non-small cell lung cancer
    Finkelstein, EI
    Urschel, JD
    Takita, H
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 1997, 16 (04) : 437 - 439
  • [5] Neoadjuvant immunochemotherapy of pembrolizumab plus chemotherapy in resectable non-small cell lung cancer
    Chen, Y.
    Yan, B.
    You, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S108 - S109
  • [6] Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): Results from the phase II PRINCEPS trial
    Besse, B.
    Adam, J.
    Cozic, N.
    Chaput-Gras, N.
    Planchard, D.
    Mezquita, L.
    Remon Masip, J.
    Lavaud, P.
    Naltet, C.
    Gazzah, A.
    de Montpreville, V. Thomas
    Ghigna, M. -R.
    Mussot, S.
    Fadel, E.
    Mabille, L.
    Duchemann, B.
    Barlesi, F.
    Soria, J-C.
    Caramella, C.
    Mercier, O.
    ANNALS OF ONCOLOGY, 2020, 31 : S794 - S795
  • [7] Accelerated neoadjuvant chemotherapy of non-small cell lung cancer (NSCLC)
    Lorusso, V
    Carpagnano, F
    diRienzo, G
    Catino, A
    Cisternino, ML
    Guida, M
    Brandi, M
    Latorre, A
    Parisi, S
    Ricco, R
    deLena, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1996, 8 (04) : 675 - 680
  • [8] Neoadjuvant nivolumab plus ipilimumab in resectable non-small cell lung cancer
    Reuss, Joshua E.
    Anagnostou, Valsamo
    Cottrell, Tricia R.
    Smith, Kellie N.
    Verde, Franco
    Zahurak, Marianna
    Lanis, Mara
    Murray, Joseph C.
    Chan, Hok Yee
    McCarthy, Caroline
    Wang, Daphne
    White, James R.
    Yang, Stephen
    Battafarano, Richard
    Broderick, Stephen
    Bush, Errol
    Brock, Malcolm
    Ha, Jinny
    Jones, David
    Merghoub, Taha
    Taube, Janis
    Velculescu, Victor E.
    Rosner, Gary
    Illei, Peter
    Pardoll, Drew M.
    Topalian, Suzanne
    Naidoo, Jarushka
    Levy, Ben
    Hellmann, Matthew
    Brahmer, Julie R.
    Chaft, Jamie E.
    Forde, Patrick M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [9] Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
    Cascone, T.
    William, W. N.
    Weissferdt, A.
    Leung, C. H.
    Federico, L.
    Haymaker, C.
    Bernatchez, C.
    Fossella, F. V.
    Mott, F. E.
    Papadimitrakopoulou, V. A.
    Byers, L.
    Lam, V. K.
    Godoy, M. C.
    Carter, B.
    Lee, J. J.
    Vaporciyan, A.
    Gibbons, D. L.
    Swisher, S. G.
    Heymach, J. V.
    Sepesi, B.
    ANNALS OF ONCOLOGY, 2018, 29
  • [10] A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non-small cell lung cancer (NSCLC).
    Owen, Dwight Hall
    Bunn, Paul A.
    Johnson, Bruce E.
    Kwiatkowski, David J.
    Kris, Mark G.
    Wistuba, Ignacio Ivan
    Gandhi, Mayank
    Phan, See
    Shames, David S.
    Schulze, Katja
    Yu, Wei
    Aisner, Dara
    Chaft, Jamie E.
    Garon, Edward B.
    Lee, Jay M.
    Minna, John D.
    Rusch, Valerie W.
    Reckamp, Karen L.
    Wozniak, Antoinette J.
    Carbone, David P.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345